Guideline‐Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome-Reference-Cited by-同舟云学术

Guideline‐Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome

Published:2018-09-18 Issue:18 Volume:7 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:J Am Heart Assoc

Author:

Hammer Yoav¹²,Iakobishvili Zaza¹²,Hasdai David¹²,Goldenberg Ilan³²⁴,Shlomo Nir⁴,Einhorn Michal⁴,Bental Tamir¹²,Witberg Guy¹²,Kornowski Ran¹²,Eisen Alon¹²

Affiliation:

1. Department of Cardiology Rabin Medical Center Petah Tikva Israel

2. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

3. The Leviev Heart Center Sheba Medical Center Tel Hashomer Israel

4. Israeli Association for Cardiovascular Trials Sheba Medical Center Tel Hashomer Israel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference24 articles.

1. Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States

2. Cardiovascular Risk Prediction in Patients With Stable and Unstable Coronary Heart Disease

3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

4. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

5. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medical calculators derived synthetic cohorts: a novel method for generating synthetic patient data;Scientific Reports;2024-05-20

2. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines;The American Journal of Medicine;2024-02

3. Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks;Frontiers in Cardiovascular Medicine;2023-02-09

4. TACE/ADAM17 substrates associate with ACS (Ep-CAM, HB-EGF) and follow-up MACE (TNFR1 and TNFR2);Atherosclerosis Plus;2022-12

5. Plasma trimethylamine-N-oxide, its precursors and risk of cardiovascular events in patients with acute coronary syndrome: Mediating effects of renal function;Frontiers in Cardiovascular Medicine;2022-09-21